Combining drugs to improve cancer treatment outcomes
Targeting the PNP - SAMHD1 synthetic-lethal combination in cancer
This study is exploring a new way to treat certain tough-to-treat cancers by using a drug called Forodesine along with another treatment that targets a specific enzyme, hoping to make the therapy work better for patients with resistant T-cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11088272 on NIH RePORTER |
What this research studies
This research investigates a new approach to cancer treatment by targeting specific enzymes involved in cancer cell survival. It focuses on the combination of a drug called Forodesine, which has shown promise in treating certain types of T-cell lymphoma, with inhibitors of another enzyme, SAMHD1, to enhance the drug's effectiveness. By understanding how these enzymes interact, the research aims to develop a more effective therapy for patients with resistant cancer types. Patients may benefit from this innovative combination therapy that could lead to improved remission rates.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with refractory or relapsed peripheral T-cell lymphoma who have not responded to standard treatments.
Not a fit: Patients with cancer types other than T-cell lymphoma or those who have not been diagnosed with refractory disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with refractory T-cell lymphomas.
How similar studies have performed: Previous studies have shown success with Forodesine in treating refractory T-cell lymphoma, indicating that this combination approach may also yield positive results.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Schramm, Vern L. — Albert Einstein College of Medicine
- Study coordinator: Schramm, Vern L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.